These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 17075808

  • 1. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis.
    Capuano A, Costanzi S, Peluso G, Zannoni G, Vellone VG, Gremese E, Zoli A, Scott C, Beltrami CA, Romano G, Ferraccioli G.
    Arthritis Rheum; 2006 Nov; 54(11):3633-9. PubMed ID: 17075808
    [Abstract] [Full Text] [Related]

  • 2. Lupus nephropathy: clinical, immunohistochemistry and quantitative morphometric analysis studies.
    Mangoud AM, Abd EE, Francis MR, Zanaty MA, Morsy AT.
    J Egypt Soc Parasitol; 2010 Aug; 40(2):321-35. PubMed ID: 21246940
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 4. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [Abstract] [Full Text] [Related]

  • 5. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

  • 6. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN.
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [Abstract] [Full Text] [Related]

  • 7. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
    Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH.
    J Rheumatol; 2002 Apr; 29(4):693-9. PubMed ID: 11950009
    [Abstract] [Full Text] [Related]

  • 8. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 10. Treatment and renal outcome of lupus nephritis: single center experience.
    Go KW, Teo SM.
    Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522
    [Abstract] [Full Text] [Related]

  • 11. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors of diffuse proliferative lupus nephritis.
    Lim CS, Chin HJ, Jung YC, Kim YS, Ahn C, Han JS, Kim S, Lee JS.
    Clin Nephrol; 1999 Sep; 52(3):139-47. PubMed ID: 10499308
    [Abstract] [Full Text] [Related]

  • 13. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis.
    Chan RW, Lai FM, Li EK, Tam LS, Wong TY, Szeto CY, Li PK, Szeto CC.
    Arthritis Rheum; 2004 Sep; 50(9):2882-90. PubMed ID: 15457456
    [Abstract] [Full Text] [Related]

  • 14. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
    Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1534-40. PubMed ID: 16449281
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of patients with biopsy-proven lupus nephritis in NUH.
    Gan HC, Hyoon K, Fong KY.
    Singapore Med J; 2002 Dec; 43(12):614-6. PubMed ID: 12693764
    [Abstract] [Full Text] [Related]

  • 16. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
    Morović-Vergles J, Galesić K, Dancuo I, Vergles D.
    Acta Med Croatica; 2004 Dec; 58(1):13-7. PubMed ID: 15125388
    [Abstract] [Full Text] [Related]

  • 17. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG, Kim HW, Cho YM, Oh JS, Nah SS, Lee CK, Yoo B.
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [Abstract] [Full Text] [Related]

  • 18. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
    Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G.
    J Clin Apher; 2002 Mar; 17(2):72-7. PubMed ID: 12210709
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
    Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L, French Vasculitis Study Group.
    Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
    [Abstract] [Full Text] [Related]

  • 20. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture.
    Naim R, Naumann A, Barnes J, Sauter A, Hormann K, Merkel D, Aust W, Braun T, Bloching M.
    Aesthetic Plast Surg; 2008 Mar; 32(2):346-52. PubMed ID: 18087663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.